Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Indian stock markets lose ground
Mon, 26 Aug 01:30 pm

Indian stock markets pared gains in last two hours of trade and are trading below the dotted line. Sectoral indices are trading mixed. Stocks from metal and IT are among leading gainers while banking and oil and gas stocks are leading the losses.

BSE-Sensex is down by 4 points and NSE-Nifty is trading up by 8 points. While BSE Mid Cap is trading up by 0.50%, BSE Small Cap index is trading up by 0.77%. The rupee is trading at 64.11 to the US dollar.

Majority of PSU banking stocks are trading in green, with Syndicate bank and Indian bank witnessing maximum buying interest. As per a financial daily, The Reserve Bank of India (RBI) on Friday penalized six PSU banks for violating know-your-customer (KYC) and anti- money laundering (AML) norms. The six PSU banks viz; Allahabad bank, Bank of Maharashtra, Corporation bank, IDBI bank,Dena bank and Indian bank were penalized by the RBI. The penalties on these banks ranged from 50 lakh to 2 crore. Apart from violating KYC and AML norms, the banks have also been found to have sold gold coins for cash of beyond 50,000. This is in non-adherence to instructions on import of gold on consignment basis. Various violating activities included not following KYC norms for walk-in customers in sale of third-party products and omitting filing of cash transaction with respect to certain transactions.

Most of the Indian pharma Stocks are trading in green, with Elder pharmaceuticals and Wockhart Ltd leading the gainers. Lupin Ltd has announced that it has received final approval for Rifampin capsules USP for 150mg and 300mg strengths from the United States Food and Drugs Administration (USFDA). The said drug is equivalent to Rifadin capsules. Rifadin brand is marketed by Sanofi Aventis, a France based company. Rifampin is indicated for the treatment of tuberculosis (TB), and for the treatment of asymptomatic carriers of Neisseria meningitides. Rifadin Capsules brand had annual U.S sales of $ 18.5 m. Lupin is one of the pioneers in the tuberculosis drugs market and holds global leadership position in the anti-TB segment. Lupin was trading down by 2.16%.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian stock markets lose ground". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.